^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Vesanoid (tretinoin)

i
Other names: ATRA, Ro 5488, NSC 122758, NSC-122758, Ro-5488, NSC122758, Ro5488
Company:
Roche
Drug class:
Cytotoxic T lymphocyte stimulant, Telomerase inhibitor, Retinoic acid receptor agonist
7d
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
|
FLT3 mutation • FLT3 wild-type
|
cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
1m
16-1080.cc: Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (clinicaltrials.gov)
P1/2, N=26, Completed, University of Colorado, Denver | Active, not recruiting --> Completed
Trial completion
|
Keytruda (pembrolizumab) • Vesanoid (tretinoin)
2ms
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications. (PubMed, Br J Haematol)
All cases were successfully managed with hydroxyurea...In conclusion, APL patients undergoing ATRA-ATO therapy with lower fibrinogen levels and platelet counts at diagnosis and with a massive bone marrow blast infiltrate should be carefully monitored for the development of leucocytosis during induction. DS and other treatment-related complications seem to occur almost exclusively in patients developing leucocytosis, who should necessarily receive DS prophylaxis and more intensive monitoring and supportive therapy to prevent treatment complications.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT expression
|
Vesanoid (tretinoin) • arsenic trioxide • hydroxyurea
3ms
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer (clinicaltrials.gov)
P1, N=10, Active, not recruiting, China Medical University Hospital | Recruiting --> Active, not recruiting | N=20 --> 10
Enrollment closed • Enrollment change
|
Opdivo (nivolumab) • Vesanoid (tretinoin)
5ms
STARPAC2: A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer (clinicaltrials.gov)
P2, N=170, Active, not recruiting, Queen Mary University of London | Not yet recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Feb 2024 --> Nov 2024
Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Stroma
|
gemcitabine • albumin-bound paclitaxel • Vesanoid (tretinoin)
5ms
New P1/2 trial • Metastases
|
Vesanoid (tretinoin)
8ms
A Study of TAS1440 With ATRA in Subjects With r/r AML (clinicaltrials.gov)
P1, N=80, Active, not recruiting, Astex Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
Vesanoid (tretinoin)
8ms
Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
Tecentriq (atezolizumab) • Vesanoid (tretinoin)
9ms
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov)
P1, N=2, Terminated, OHSU Knight Cancer Institute | Active, not recruiting --> Terminated; Low accrual
Trial termination
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Venclexta (venetoclax) • Lynparza (olaparib) • Mekinist (trametinib) • erlotinib • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • sorafenib • Rozlytrek (entrectinib) • imatinib • sunitinib • everolimus • Nerlynx (neratinib) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Lorbrena (lorlatinib) • Lenvima (lenvatinib) • bortezomib • doxorubicin hydrochloride • capecitabine • Verzenio (abemaciclib) • Xtandi (enzalutamide capsule) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Stivarga (regorafenib) • abiraterone acetate • oxaliplatin • Aliqopa (copanlisib) • Vizimpro (dacomitinib) • Zydelig (idelalisib) • daunorubicin • Zolinza (vorinostat) • Idhifa (enasidenib) • Farydak (panobinostat) • Erivedge (vismodegib) • Nubeqa (darolutamide) • bicalutamide • leucovorin calcium • cabazitaxel • Vesanoid (tretinoin) • fluorouracil topical
9ms
A machine learning model identifies M3-like subtype in AML based on PML/RARα targets. (PubMed, iScience)
M3-like patients exhibited distinct genomic features, low immune activity and better clinical survival. The initiative identification of patients similar to M3 subtype may help to identify more patients that would benefit from ATO/ATRA treatment and deepen our understanding of the molecular mechanism of AML pathogenesis.
Journal • Machine learning
|
RARA (Retinoic Acid Receptor Alpha)
|
Vesanoid (tretinoin)
10ms
The Potential Transcriptomic and Metabolomic Mechanisms of ATO and ATRA in Treatment of FLT3-ITD Acute Myeloid Leukemia. (PubMed, Technol Cancer Res Treat)
The gene transcription profile and metabolites of FLT3-ITD mutant cells changes significantly after treatment, which might be related to the anti-FLT3-ITD AML effect. The screened DEGs, differential metabolites pathway are helpful in studying the mechanism of anti-leukemia effects and drug targets.
Journal • Metabolomic study
|
FLT3 (Fms-related tyrosine kinase 3) • VDAC1 (Voltage Dependent Anion Channel 1)
|
FLT3-ITD mutation
|
Vesanoid (tretinoin) • arsenic trioxide
11ms
Enrollment closed • Combination therapy
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Vesanoid (tretinoin) • quavonlimab (MK-1308) • vibostolimab (MK-7684)
11ms
Enrollment closed • Combination therapy
|
Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
12ms
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Oct 2025 --> Sep 2024
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
|
FLT3 mutation • FLT3 wild-type
|
cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
1year
Pharmacokinetic assessment of convection-enhanced delivery of small molecule drugs for H3 K27-altered diffuse midline glioma (SNO 2023)
A panel of FDA-approved drugs with biologically validated activity in DMG were selected for each group: panobinostat/ponatinib, everolimus/topotecan, tolnaftate/tretinoin, and carmofur/eltrombopag...These properties were further validated in efficacy studies in DMG animal models. The proclivity of many drugs to be rapidly effluxed from the brain after CED generates a vulnerability that can be exploited for the development of novel therapeutic regimens, such as with pharmacokinetics-informed drug selection or concomitant dosing of ET-inhibiting drugs.
PK/PD data
|
everolimus • Iclusig (ponatinib) • topotecan • Farydak (panobinostat) • Vesanoid (tretinoin) • Promacta (eltrombopag)
1year
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (clinicaltrials.gov)
P2, N=112, Recruiting, Mario Negri Institute for Pharmacological Research | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
anastrozole • Vesanoid (tretinoin)
1year
16-1080.cc: Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (clinicaltrials.gov)
P1/2, N=26, Active, not recruiting, University of Colorado, Denver | Trial completion date: Aug 2023 --> Aug 2024
Trial completion date • Metastases
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • ITGAM (Integrin, alpha M)
|
Keytruda (pembrolizumab) • Vesanoid (tretinoin)
1year
Trial completion date
|
RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
|
Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
1year
Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center. (PubMed, J Cancer Res Ther)
Both options of treatment (ATRA-ATO and ATRA-chemotherapy) were discussed with patients with low- and intermediate-risk APL, pros and cons explained in details, and treatment regimen selected after getting informed written consent. Fifteen patients liked to be treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), while rest of the 15 patients preferred treatment with ATRA and chemotherapy. Combination of ATRA and ATO is equally effective, less toxic, and more feasible in comparison to ATRA and chemotherapy for patients with low- and intermediate-risk APL and is a viable option for this subset of patients, especially in countries with limited resources.
Journal
|
RARA (Retinoic Acid Receptor Alpha)
|
Vesanoid (tretinoin) • arsenic trioxide
1year
Venetoclax Upregulates Mitochondrial Stress Response to Overcome the Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia (SOHO 2023)
Immunoblotting confirmed that ATO-resistant cells were unable to undergo apoptosis as levels of pro-apoptotic (cleaved caspase-3, cleaved-PARP, BAX), anti-apoptotic (Bcl2, Bcl-xL, XIAP), and PML-RARA proteins remain unchanged in ATO-resistant cells except for downregulation of Bcl2 and upregulation of cleaved caspase-3 in UF1 following ATO/ATRA treatment. Our results indicate that venetoclax+ATO cooperates in inducing apoptosis of ATO-resistant cells through mitochondrial stress-induced ROS production coupled with PML-RARA degradation.
PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • PML (Promyelocytic Leukemia) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
PML-RARA A216V
|
Venclexta (venetoclax) • Vesanoid (tretinoin) • arsenic trioxide
1year
Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO). (PubMed, Cancers (Basel))
Even in the case of relapses, most patients obtain a new remission as a result of therapy with ATO and ATRA, but an effective consolidation treatment is necessary to maintain it. However, there is a variety of controversial aspects related to the role of HSCT in APL, ranging from the fact that outcome data are obtained almost exclusively from retrospective studies and historical analyses to questions related to the type of transplantation, the impact of minimal residual disease, conditioning regimens, or the role of other therapeutic options. All these questions justify the need for controlled prospective studies in the following years.
Review • Journal
|
Vesanoid (tretinoin) • arsenic trioxide
over1year
Management of Acute Promyelocytic Leukemia at Extremes of Age. (PubMed, Cancers (Basel))
Tailored treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the outcome of acute promyelocytic leukemia (APL) from a uniformly fatal disease to one of the most curable malignant diseases in humans. Due to its high efficacy, ATO/ATRA is the standard first-line therapy in younger adult, non-high-risk APL patients...Besides the treatment of newly diagnosed patients, managing toxicities and complications remains challenging. This review discusses the approach to the treatment of APL in elderly and pediatric patients.
Review • Journal
|
Vesanoid (tretinoin) • arsenic trioxide
over1year
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away. (PubMed, Cancers (Basel))
Since the introduction of all-trans retinoic acid (ATRA), acute promyelocytic leukemia (APL) has become a highly curable malignancy, especially in combination with arsenic trioxide (ATO)...Furthermore, recent super-enhancer (SE) analysis has identified a novel AML subgroup characterized by high expression of RARα through strong SE levels in the gene locus and increased sensitivity to tamibarotene. Combined with a hypomethylating agent, synthetic retinoids have shown synergistic anti-leukemic effects in non-APL AML preclinical models and are now being studied in phase II and III clinical trials.
Review • Journal
|
RARA (Retinoic Acid Receptor Alpha) • CYP26A1 (Cytochrome P450 Family 26 Subfamily A Member 1)
|
Vesanoid (tretinoin) • arsenic trioxide • Amnolake (tamibarotene)
over1year
Arsenic-Containing Medicine Treatment Disturbed the Human Intestinal Microbial Flora. (PubMed, Toxics)
We explored the overall microbial flora by 16S rRNA genes analysis in fecal samples from acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA)...In the most common gut bacteria Bacteroides fragilis, arsenic resistance genes were significantly induced by arsenic exposure in anaerobic pure culture experiments. Without an animal model, without taking arsenicals passively, the results evidence that arsenic exposure by drug treatment is not only associated with alterations in intestinal microbiome development at the abundance and diversity level, but also induced arsenic biotransformation genes (ABGs) at the function levels which may even extend to arsenic-related health outcomes in APL.
Journal
|
Vesanoid (tretinoin) • arsenic trioxide
over1year
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov)
P1, N=2, Active, not recruiting, OHSU Knight Cancer Institute | Recruiting --> Active, not recruiting | N=40 --> 2 | Trial completion date: Feb 2026 --> Jun 2027 | Trial primary completion date: Feb 2023 --> Jun 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Venclexta (venetoclax) • Lynparza (olaparib) • Mekinist (trametinib) • erlotinib • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • sorafenib • Rozlytrek (entrectinib) • imatinib • sunitinib • everolimus • Nerlynx (neratinib) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Lorbrena (lorlatinib) • Lenvima (lenvatinib) • bortezomib • doxorubicin hydrochloride • capecitabine • Verzenio (abemaciclib) • Xtandi (enzalutamide capsule) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Stivarga (regorafenib) • abiraterone acetate • oxaliplatin • Aliqopa (copanlisib) • Vizimpro (dacomitinib) • Zydelig (idelalisib) • daunorubicin • Zolinza (vorinostat) • Idhifa (enasidenib) • Farydak (panobinostat) • Erivedge (vismodegib) • Nubeqa (darolutamide) • bicalutamide • leucovorin calcium • cabazitaxel • Vesanoid (tretinoin) • fluorouracil topical
over1year
Pediatric APL (ICLLM 2023)
The use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is highly effective making this now the most curable subtype of AML...On COG AAML1331, pediatric patients with HR APL were enrolled on a treatment arm that included the anthracycline idarubicin only in induction using a ATO-ATRA based regimen without maintenance therapy...Standard risk APL using a cytotoxic free ATO-ATRA induction also frequently results in hyperleukocytosis (elevated white blood cell count from blast differentiation) requiring cytoreduction. Thus, careful monitoring of these potential complications and aggressive supportive care to correct coagulopathy and treat differentiation syndrome and/or hyperleukocytosis is critical to prevent early death and ensure excellent cure rates.
Clinical
|
PML (Promyelocytic Leukemia)
|
Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
|
idarubicin hydrochloride • Vesanoid (tretinoin) • arsenic trioxide
over1year
ANALYSIS OF FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY (EHA 2023)
Background: APL, once regarded as the most rapidly fatal acute myeloid leukemia (AML), is now curable in 75-90% of patients using targeted agents [All-trans retinoic acid (ATRA)+Arsenic Trioxide (ATO)] or ATRA combined with chemotherapy (ATRA+Idarubicin, AIDA-based). This first analysis on the Harmony APL project shows a significant survival advantage of patients treated with the ATRA-ATO chemo-free regimen at 10 year-follow-up, irrespective of the Sanz-risk score. The latter maintains its prognostic relevance in patients treated with the AIDA regimen. Age resulted significantly associated with OS, irrespective of treatment.
Clinical
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation
|
idarubicin hydrochloride • Vesanoid (tretinoin) • arsenic trioxide
over1year
NOT ALL VARIANTS OF ACUTE PROMYELOCYTIC LEUKEMIAS ARE RESISTANT TO RETINOIDS. (EHA 2023)
He was found to have persistent leukocytosis despite treatment with IV ampicillin–sulbactam...He was started on induction therapy with ATRA at 45mg/m 2 /day in 2 divided doses, systemic chemotherapy with 4 doses of idarubicin (12mg/m 2 on day 1,3,5,7), followed by arsenic trioxide (ATO) on day 8 at 0.15 mg/kg IV daily until hematological response. He received a brief course of cytoreductive therapy with hydroxyurea 1500 mg twice daily during the initial phase of treatment for high-risk APLv (white cell count >10 × 10⁹/l)...He was managed as differentiation syndrome with dexamethasone and symptomatic improvement within 24 hours of initiation of steroid therapy...2010; 115(25):5137-5146) based consolidation regimen was chosen with addition of cytarabine combined with ATRA and idarubicin in the 1 st and 3 rd consolidation cycles for a total of 3 monthly cycles. BM biopsy at cell count recovery with platelets (> 100x10 9 /L) and neutrophils (> 1x10 9 /L) post-induction showed complete remission with a morphologic response (<5% blasts) and normal cytogenetic analysis. Despite the achievement of complete morphologic remission, there were concerns for the relative refractoriness of the APLv to ATO+ATRA alone, although scant with fewer data on ATO sensitivity. Thus, a chemotherapy-based consolidation approach was chosen vs ATRA+ATO alone.
IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • RARA (Retinoic Acid Receptor Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
|
cytarabine • methotrexate • dexamethasone • idarubicin hydrochloride • Vesanoid (tretinoin) • arsenic trioxide • hydroxyurea • mercaptopurine
over1year
ORAL-ATO/ATRA/ASCORBIC ACID (AAA)-BASED INDUCTION OR MAINTENANCE OF FIRST COMPLETE REMISSION IMPROVED OUTCOMES IN NEWLY DIAGNOSED APL: A MULTICENTRE ANALYSIS OF THE APL ASIAN CONSORTIUM (APLAC) (EHA 2023)
The use of AAA-based regimens in newly-diagnosed APL significantly improved early deaths, OS and RFS independent of conventional risk grouping. Acute promyelocytic leukemia, Oral, Arsenic trioxide, ALL-trans retinoic acid (ATRA)
Clinical
|
Vesanoid (tretinoin)
over1year
INCIDENCE, RISK FACTORS AND OUTCOMES OF SECOND NEOPLASMS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: THE PETHEMA-PALG EXPERIENCE. (EHA 2023)
We performed a retrospective analysis of 2670 unselected APL patients, diagnosed and treated with PETHEMA protocols: chemotherapy based (APL1996, 1999, 2005, 2012 and 2017 for high risk) and "chemo free" ATO+ATRA (2017 for low/intermediate risk). The s-NPLs are relatively frequent and severe late complication in APL. Age >= 35 years is a potential risk factorfor development of s-NPLs. Chemotherapy free regimens had lower CI of s-NPLs at 5 years, nevertheless more data and follow-up are required.
Clinical
|
Vesanoid (tretinoin) • arsenic trioxide
over1year
RESULTS OF NON-CHEMOTERAPEUTIC TREATMENT OF PATIENTS WITH DE NOVO ACUTE PROMYELOCYTIC LEUKEMIA (EHA 2023)
Patients from the high-risk group got idarubicin 8–12 mg/m2 (1–3 administrations) at the beginning of the induction course for cytoreduction, and patients with clinically significant hyperleukocytosis got cytarabine 100 mg/m2 (1–3 administrations). Risk-adapted strategy for non-chemotherapeutic treatment of acute promyelocytic leukemia based on combination of tretinon and arsinic trioxide allows to achieve 99.0% 3-year disease-free survival in patients as from the low-risk group as from the high-risk group. The main reason for unsuccessful therapy according to the ATO+ATRA protocol was early mortality in patients from the high-risk group. ALL-trans retinoic acid (ATRA), Acute promyelocytic leukemia, Arsenic trioxide
Clinical
|
cytarabine • idarubicin hydrochloride • Vesanoid (tretinoin) • arsenic trioxide
over1year
AN ENTIRELY ORAL REGIMEN OF ORAL-ATO, ATRA AND ASCORBIC ACID IN RISK-ADAPTED TREATMENT OF NEWLY-DIAGNOSED APL RESULTED IN EXCELLENT CLINICAL/MOLECULAR RESPONSES WITH DURABLE REMISSION (EHA 2023)
Daunorubicin (50mg/m 2 /day intravenously for 3 days) was administered to patients < 65 years old with high-risk disease. The use of an entirely oral AAA-based induction in a risk-adapted strategy that minimized chemotherapy was highly effective and safe in newly-diagnosed APL of all risk categories, and induced deep molecular responses. ALL-trans retinoic acid (ATRA), Oral, Acute promyelocytic leukemia, Arsenic trioxide
Clinical
|
daunorubicin • Vesanoid (tretinoin)
over1year
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (clinicaltrials.gov)
P2, N=112, Recruiting, Mario Negri Institute for Pharmacological Research | Unknown status --> Recruiting | Trial completion date: Jun 2021 --> Sep 2023 | Trial primary completion date: Jun 2021 --> Aug 2023
Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
anastrozole • Vesanoid (tretinoin)
almost2years
Treatment Outcomes Of Patients With Newly Diagnosed Acute Promyelocytic Leukemia; Experience From A Developing Country. (PubMed, J Ayub Med Coll Abbottabad)
Our study shows APL is a highly curable malignancy and outcomes have improved with newer non chemotherapy based therapies. It can also be concluded that outcomes of APL gradually improved over the past 2 decades due to improvement in supportive care, provision of blood products and use of newer protocols. The prognosis remains less favourable in high risk patients.
Journal
|
PML (Promyelocytic Leukemia)
|
Vesanoid (tretinoin) • arsenic trioxide
2years
Long-Term Real-World Outcomes of Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide and All Trans Retinoic Acid without Chemotherapy (ASH 2022)
Hydroxyurea was given for cytoreduction (up to 2gm q2hourly) on physician discretion if the TLC>5x109/L...Patients with Intermediate and High-risk disease received 2 years of maintenance with ATRA for 15 days once every 3 months, daily 6-Mercaptopurine and weekly oral Methotrexate. After a protocol modification in 2015, oral Prednisolone (0.5-1mg/kg/day for 14 days followed by taper) was added to the induction therapy and maintenance therapy was reduced to 1 year...The estimated 5-year EFS and OS in the entire cohort were 79 ± 5.8% and 80 ± 5.8%, respectively. CONCLUSION Treatment of all risk classes of APML with ATO and ATRA without chemotherapy is associated with excellent long-term outcomes in the real-world setting.
Clinical • Real-world evidence
|
PML (Promyelocytic Leukemia)
|
methotrexate • Vesanoid (tretinoin) • arsenic trioxide • hydroxyurea • mercaptopurine • prednisolone
2years
Oral Realgar-Indigo Naturalis Formula Versus Intravenous Arsenic Trioxide for Non-High-Risk Patients with Acute Promyelocytic Leukemia: Interim Results of a Multicenter Randomized Controlled Trial APL16 (ASH 2022)
Then they were randomized to receive consolidation therapy including ATRA plus ATO or ATRA plus RIF. Interim results of this study proved efficacy of ATRA plus RIF was non-inferior to ATRA plus intravenous ATO for consolidation therapy in standard-risk APL. The toxicity is almost equivalent except slightly advantage of ATRA-RIF group on coagulation. No relapses may be attributed to simultaneous administer of ATRA and ATO/RIF.
Clinical
|
PML (Promyelocytic Leukemia)
|
PML-RARA fusion
|
Vesanoid (tretinoin) • arsenic trioxide
2years
Clinical Genomic Analyses Demonstrate t(11; 14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax (ASH 2022)
Using an integrated approach of transcriptomic and metabolomic profiling, t(11; 14) MM cells were confirmed to retain features of B-cell biology, including lower Mito metabolism that results in increased sensitivity to BCL-2 inhibition by Ven. Although these biological features are closely linked to t(11; 14), B-cell gene or Mito gene signatures did not serve as better biomarkers for predicting efficacy to Ven compared with t(11; 14) alone.
Clinical • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • SDC1 (Syndecan 1)
|
BCL2 expression • CD20 expression • CCND1 expression • CCND1-H
|
Venclexta (venetoclax) • Vesanoid (tretinoin)
2years
Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα. (PubMed, Acta Pharmacol Sin)
The acute promyelocytic leukemia (APL) driver ZBTB16/RARα is generated by the t(11;17) (q23;q21) chromosomal translocation, which is resistant to combined treatment of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) or conventional chemotherapy, resulting in extremely low survival rates...We showed that Z/R fusion protein expressed in HeLa cells was resistant to ATO, ATRA, and conventional chemotherapeutic agents...Furthermore, SIAH2 was identified as the E3 ligase participating in hyperthermia-induced ubiquitination of ZBTB16/RARα. In short, these results demonstrate that hyperthermia could effectively destabilize and subsequently degrade the ZBTB16/RARα fusion protein in an NCoR-dependent manner, suggesting a thermal-based therapeutic strategy that may improve the outcome in refractory ZBTB16/RARα-driven APL patients in the clinic.
Journal
|
RARA (Retinoic Acid Receptor Alpha) • ZBTB16 (Zinc Finger And BTB Domain Containing 16)
|
Vesanoid (tretinoin) • arsenic trioxide
2years
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2025
Trial completion date • Trial primary completion date
|
RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
|
Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
over2years
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment (clinicaltrials.gov)
P2, N=14, Completed, Icahn School of Medicine at Mount Sinai | Active, not recruiting --> Completed
Trial completion
|
GAS6 (Growth arrest specific 6) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
|
azacitidine • Vesanoid (tretinoin) • leuprolide acetate for depot suspension
over2years
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment (clinicaltrials.gov)
P2, N=14, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Recruiting --> Active, not recruiting | N=20 --> 14 | Trial primary completion date: Feb 2022 --> May 2022
Enrollment closed • Enrollment change • Trial primary completion date
|
GAS6 (Growth arrest specific 6) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
|
azacitidine • Vesanoid (tretinoin) • leuprolide acetate for depot suspension